Search

While addressing the symposium Chancellor of UIT University Mr. Hussain Hasham said that the World is changing very fast with new technologies that's why UIT University is thinking about immerging in the new field of BioScience, Biotechnology, and bio Engineering. UIT University organized a one-day Symposium on Saturday 29th April, In the symposium guest speakers highlighted the recent developments in Genetic and Bio-engineering that are likely to bring drastic changes to society in the near future, much like how computer technology has transformed the world. [Extracted from the article]

The article offers information on the growing threat of biological weapons in the age of synthetic biology and its potential to surpass nuclear weapons in destruction. Topics discussed include the rise of bioweapons in Russia and China; the challenges of current bioweapons deterrence strategies; and the importance of establishing a robust biological intelligence (BIOINT) system to detect and respond to biological threats.

President Joe Biden appointed Ryan Panchadsaram, a South Asian American engineer and investor, to the National Science Board. Panchadsaram has a background in business and government, including serving as Deputy Chief Technology Officer during the Obama-Biden Administration. In a separate development, Elon Musk's Starlink Inc. secured a win in India's satellite broadband market, with the government opting for spectrum allocation over auction, sparking a battle with local wireless operators. [Extracted from the article]

The article reports on the publication of "The Brave New World of Synthetic Biology," by Arthurd D. Little (ADL) from the company's Blue Shift institute, which explores the impact of new technologies on business, society and people. Topics discussed include information on Synthetic Biology and purpose of the report.

The article reports that DIC Corp. has announced the start of joint business development in the area of polyphenols with California-based biotech startup Debut, a vertically integrated synthetic biology company at the forefront of advanced biomanufacturing technology. It mentions polyphenols will be produced using an innovative biotechnology for use in the cosmetics and nutrition industries. It also mentions DIC and Debut will begin construction of a biomanufacturing facility in the U.S.

The article focuses on Debut, a synthetic biology company, securing million dollars in Series B funding led by L'Oréal's venture capital fund, BOLD. It aims to revolutionize the fragrance industry and establish Debut's biotech fragrance model as a benchmark. It emphasizes on their proprietary biomanufacturing platform and strategic entry into the fragrance category, marking a significant step in advancing synthetic biology in cosmetics.

The article reports that Provectus Algae received a strategic investment from CJ BIO, a division of South Korea-based food & bio company CJ CheilJedang. It mentions company intends to use the funds to accelerate commercialization efforts that bring innovative specialty ingredients to market. It also mentions company has also developed a synthetic biology stack that complements and competes with existing production platforms to deliver sustainable products.

The article reports on the 34 million dollars in fund raised by Debut Biotechnology Inc. in a Series B round led by the venture capital arm of cosmetics firm L'Oréal.

The article informs that ADM is making a leading equity investment in Acies Bio, for developing and scaling synthetic biology and precision fermentation technologies for food, agriculture and industrial applications. It mentions this investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio's extensive microbial capabilities and contract manufacturing services.

The article features the acquisition by Codex DNA of synthetic biology firm Eton Bioscience for 13 million dollars in November 2021. Topics covered include the its enabling of Codex to expand its commercial BioXp system, reduce raw material costs, and accelerate growth, and Eton's specialization in gene sequencing. Also noted are the profiles of the two companies.

The article reports that Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks, the leading horizontal platform for cell programming, as supply agreement expanding collaboration between leading organizations in the synthetic biology ecosystem. It mentions that four-year agreement includes an increased commitment by Ginkgo to purchase products from synthesis capacity to meet Ginkgo's growth.

The article highlights the collaboration between Cochin University of Science and Technology (Cusat) and Synthite Industries to establish a worldwide center of excellence, named C.V. Jacob Centre for Synthetic Biology and Biomanufacturing (CSB), which will specialize in various scientific fields.

The article focuses on synthetic biology as of 2013 and how it has developed into a growing scientific field. The author discusses how Jim Collins, professor of biomedical engineering at Boston University, essentially developed the field of study by combining biology and engineering. He explores how Collins, student Tim Gardner, and director of the Human Genome Project Bill Cantor created a "switch" for growing DNA, notes the work of Collins and Massachusetts Institute of Technology (MIT) engineering student Tim Lu on discovering the molecular causes of disease, and examines the future of the discipline.

The article discusses Synthetic Biology (Synbio) has enabled creation of organisms that use fermentation to produce a wide variety of chemicals from renewable feedstock. It mentions that products in later stages of development can leverage the environmental and marketing benefits of the technology; and technology limitations and real and perceived ill-effects of traditional petrochemical synthesis, have led to alternative models of chemical production, including synthetic biology (synbio).

The article describes the creative works of Neri Oxman, a U.S. architect, artist and professor at the Massachusetts Institute of Technology's Media Laboratory. She founded a discipline she calls material ecology, which combines computational design, synthetic biology and three-dimensional printing to create compostable structures and glass objects that vary their optical and structural properties, among other designs. The objects have been featured in design fairs, fashion shows and museums.

The article discusses research that examined the efficacy of a synthetic biology-based treatment for phenylketonuria (PKU). Topics covered include the use of engineered bacteria to break down a naturally occurring toxin in the blood, the traditional treatment for PKU, and Synlogic's clinical testing of the synthetic biology-based treatment.

The article reports that Sumitomo Chemical has announced plans to establish SynBio Hub within its Biorational Research Centre as a part of the firm's plans to build technologies using synthetic biology. It mentions responsibility for biorational-related business to its Valent BioSciences (VBC) subsidiary in Illinois. It also mentions Sumitomo Chemical is developing highly functional products that cannot be manufactured by chemical synthesis and energy-saving processes.

The article reports on the establishment of a new joint research laboratory by world's largest manufacturer of oleochemicals Wilmar International Ltd. and the National University of Singapore (NUS) to conduct cutting-edge clinical nutrition and synthetic biology research. The goal to create healthier food products and to devise green production technologies for industrial enzymes and biochemicals is tackled. NUS President Professor Tan Eng Chye also comments on the said initiative.

The article lists the winners of silver medal at in the international Genetically Engineered Machines contest at the Giant Jamboree for their project on Tuberculosis diagnostics through synthetic biology including Aarti Kejriwal, Avani Koparkar, and Yash Joshi.

The article discusses the development of a technique in which genetically modified yeast is used to turn sugar into morphine, noting concerns about the implications for the production of heroin. Topics addressed include potential government regulation of the process, as well as the publication of synthetic biology on how to grow (S)-reticuline in brewer's yeast (Saccharomyces cerevisiae).

The article presents a new market research being conducted by consulting firms Kline & Co. and Promotum Inc. on the emergence of ways on how personal care ingredients are sourced and synthesised. The said report is first part of a series analysing the impact of synthetic biology on the speciality chemical and allied industries. The revolution is considered a collision of genetics, information science, and robotics.

The article discusses the synthetic biology being developed by Synthorx Inc., a small biotechnology company in San Diego, California. The company chief executive officer (CEO) Court Turner compares the tool of synthetic biology for drug development with the creation of new and faster computer electronic chips. The tool is a synthetic DNA base called X-Y technology, which was developed by professor Floyd Romesberg. The company gains exclusive rights to such technology.

The article discusses the use of synthetic biology to create ingredients used in consumer products. Topics discussed include the use of algae-produced oil as a replacement for palm oil in products by ecological cleaning products company Ecover and biotechnology company Solazyme, the views of Ecover manager of long-term innovation Tom Domen, and the response from consumer advocacy groups.

The article discusses the analysis done by the research and advisory firm Lux Research revealing that the flavors & fragrances (F&F) industry of worth $25-bn is utilizing synthetic biology and biotechnology to restore it's high-risk and -cost path, citing the processes of enzymatic transformation and fermentation of F&F production methods. It also discusses the views of the associate Meraldo Antonio of Lux Research in this issue.

The article informs that according to a Lux Research analysis, synthetic biology start-ups need 7.4 years to launch first chemical product who are working on developing technologies to convert biomass feedstocks into chemicals. It mentions views of Julia Allen, Lux Research analyst, on how first wave of bio-based materials and product launches provide valuable insights. It reveals that Oakbio, Global Bioenergies are nearing the average time for launches.

The article discusses the creation of flavors and scents associated with various exotic plants by using synthetic biology to genetically re-engineer yeast and other microorganisms as of October 20, 2013. Topics addressed include concerns regarding the economic effects of the process on farmers in developing countries; debate over whether the engineered products can be labeled as natural; and the production of vanillin, pharmaceuticals, and orange and grapefruit flavors.

The article discusses a project conducted by biotechnology hobbyists and entrepreneurs that uses synthetic biology to create bioluminescent plants. Information is provided on the project's funding through the crowd sourcing website Kickstarter as well as opposition from the environmental organizations Friends of the Earth and the ETC Group. Comments from project manager Antony Evans are included.

The article provides information on the International Genetically Engineered Machine (iGEM) competition, which allows teams of undergraduate students to explore ideas related to synthetic biology, held on the campus of the Massachusetts Institute of Technology (MIT) in the fall of 2012. Projects highlighted in the article focus on topics including fabricated DNA sequences, genetic engineering of food, and ethical issues related to synthetic biology and genetic research.

The article focuses on the development of the International Genetically Engineered Machine (iGEM) by integrating engineering principles to synthetic biology at the Massachusetts Institute of Technology (MIT). According to Meagan Lizarazo, vice-president of the iGEM Foundation, the Registry of Standard Biological Parts provide genetic parts to the iGEM and academic laboratories. As stated, the iGEM will be expanded to five regions in 2012 including North America West, Latin America and Europe.

The article reports on synthetic biology and explores ways in which research into this field by universities and institutions can lead to developing more effective and efficient medicines, renewable resources, and energy sources. A brief history of genetic experimentation in organisms is provided and research on genetic structuring by biomedical engineer James J. Collins, cancer cell elimination by biological engineer Ron Weiss, and artemisinin development, a malaria drug, by chemical engineer Jay D. Keasling are highlighted. Other topics include the moral and ethical aspects of biomedical research, human DNA genome research by scientist J. Craig Venter, and corporate and public funding for synthetic biology research.

The article reports that scientists at the Craig Venter Institute have created the world's first completely synthetic organism. David Magnus of the Stanford University Center for Biomedical Ethics said the development could have a broad impact on genetic engineering. Institute founder Craig Venter said he planned to obtain a patent on his single-cell creation.

Several letters to the editor are presented in response to articles in previous issues including "Restoration Drama," by Penelope Green in the February 7, 2013 issue, "Dormant but not Forgotten," by Michael Tortorello in the January 24, 2013 issue and "The Beauty of Bacteria," by Julie Lasky in the January 17, 2013 issue.

This article discusses the use of synthetic biology research in plastics creation, the development of virus-resistance in humans, and the revival of extinct animal species, adapted from the book "Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves," by George Church and Ed Regis.

Synthetic biology -- which includes the development of fuels, organ tissue and tumor-destroying bacteria -- became a focus of government and law enforcement agencies after 9/11 and the anthrax attacks that quickly followed it. The field's ''extraordinary promise,'' a presidential commission concluded in December, is accompanied by ''potential risks'' to humans and the environment. Even worse, it is possible that such designer organisms could fall into the hands of a ''deranged individual or terrorist, who could create and release a deadly virus, said Richard H. Ebright, a professor of chemistry and chemical biology at Rutgers University. The potential for such a chain of events has cast a pall over the discipline, he said. [ABSTRACT FROM PUBLISHER]

Synthetic biology, the quest to hijack living systems and convert them to human-directed goals, is on the march. Last year biologists synthesized the entire genome of a small bacterium and showed how it could successfully infect a second bacterium. Now, in what may be a more significant advance, biologists have shown they can radically change a genome, not just copy it. A team led by Farren J. Isaacs and George M. Church of the Harvard Medical School has devised a method for making hundreds of changes in a genome simultaneously. This massively parallel intervention, as the changes are known, is one of the advances that would be needed in another project Dr. Church and others have contemplated, that of recreating the mammoth by starting with an elephant's genome and changing it at the 400,000 sites at which elephant DNA differs from that of the mammoth. [ABSTRACT FROM PUBLISHER]

The president's bioethics commission has concluded that there is no need to temporarily halt research or to impose new regulations on the controversial new field known as synthetic biology. In a report issued Thursday, the Presidential Commission for the Study of Bioethical Issues said that at present the technology -- which involves creating novel organisms through the synthesis and manipulation of DNA -- poses few risks because it is still in its infancy. [ABSTRACT FROM AUTHOR]

The president's bioethics commission says there is no need to temporarily halt research or to impose new regulations on the controversial new field known as synthetic biology. In a report being issued Thursday, the Presidential Commission for the Study of Bioethical Issues says that at present the technology -- which involves creating novel organisms through the synthesis and manipulation of DNA -- poses few risks because it is still in its infancy. [ABSTRACT FROM AUTHOR]

The article discusses the progress made in synthetic biology. In a study by James J. Collins and his team at Boston University, they taught E. coli bacteria to count by inserting custom-designed DNA into the bacteria that induces it to emit a fluorescent protein after being exposed to a specific number of chemical pulse. It relates the applications and potential downside of synthetic biology.

The article reports on the research plans of the National Center for Bio-Security of the Australian National University in Canberra and the University of Sydney in New South Wales for 2008. As stated, the center will investigate synthetic biology and combat various infectious diseases, potential biological warfare and the misuse of research. Also, the researchers will examine the agents of concern like anthrax, plaque and botulism-causing toxin.

The article reports that Harvard University received $125 million from medical-device billionaire Hansjorg Wyss making the endowment the largest one-time gift in the history of the institution. Mr. Wyss graduated from Harvard Business School in 1965. He already provided $25 million to the business school in 2004 for doctoral projects. The Institute for Biologically Inspired Engineering will be renamed after Mr. Wyss according to the school. The focus of the center is on synthetic biology such as biological materials and devices.

The article focuses on a genetic-engineering competition called the International Genetically Engineered Machine Competition (iGEM) and discusses its goal. The point of the competition is to determine whether biological organisms and devices can be constructed from standard parts. Students in the competition are helping to build the field of synthetic biology. iGEM was held at the Massachusetts Institute of Technology (MIT) and founded by all MIT faculty members. Attention is paid to biobricks, or a library of DNA bits of information, that have been engineered to snap together with other library parts. iGEM's director Randy Rettberg explains that biobricks will eliminate the unpredictability of genetic engineering. Leader of sequencing the human genome J. Craig Venter is also mentioned.

The article offers information regarding biotechnology foundries or fabs that produce synthetic DNAs containing instructions for living creatures for their customers including the pharmaceutical industry and academic scientists. It refers to the increase in the sales of the gene-synthesis industry and states that the cost per DNA pair has come down to less than $1 from $ 30.

The article offers information regarding the increasing trend of testing drugs and cosmetics on human tissues. It states that owing to fast technological innovations, the tests are being conducted on engineered tissues, computer software or volunteers. The alternatives are said to be better as they save animals used for the purpose.

The article informs about synthetic biology. It is an effort by genetic engineers to rewire the genetic circuitry of living organisms. The undertaking includes insertion of one to two genes into a bacterium or crop plant. Synthetic biologists plan to include microbes modified to generate cheap petroleum out of plant waste and design whole organisms from scratch. They can identify a network of useful genes on their computer screens by downloading the gene sequences filed in DNA data banks.